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Background: Data on effect of regular liver function monitoring during anti-TB treatment is limited in China. This
study aimed to evaluate the effects of scheduled liver function monitoring on identification of asymptomatic liver
damage and anti-TB treatment outcomes during anti-TB treatment.
Methods: A retrospective analysis was performed based on a national-level cohort study. A total of 273 patients
developing liver dysfunction were divided into two groups, 111 patients who were diagnosed through scheduled
liver function test within two months after initiation of anti-TB treatment formed scheduled monitoring group,
others who were diagnosed due to developing symptoms formed passive detection group (n = 162). The two
groups were compared through clinical features, prognosis of liver dysfunction and impact on anti-TB treatment
using propensity score weighting analysis.
Results: 33.3% of 273 patients did not have any clinical symptoms, including 8 with severe hepatotoxicity. 1.8% in
scheduled monitoring group and 11.1% in passive detection group required hospitalization (P = 0.004). Regarding
the prognosis of liver dysfunction, most patients recovered, no death happened in scheduled monitoring group
while 3 died in passive detection group. In terms of impact on anti-TB treatment, 35.1% in scheduled monitoring
group and 56.8% in passive detection group changed their anti-TB treatment (P = 0.001).
Conclusions: Scheduled monitoring is effective in identifying asymptomatic liver damage, reducing hospitalization
rate and improving compliance of anti-TB treatment.
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Tuberculosis (TB) is one of the most common infectious
diseases worldwide, especially in developing countries.
According to WHO reports, there were an estimated 8.5-
9.2 million incident cases and 1.2-1.5 million deaths (in-
cluding deaths from TB among HIV-positive people) in
2010[1]. As the second highest TB burden country in the
world, China accounted for an estimated 12% of all TB
cases worldwide [1]. China national surveys found a preva-
lence rate of bacteriologically-confirmed pulmonary TB of* Correspondence: siyan-zhan@bjmu.edu.cn
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reproduction in any medium, provided the or119 (113–135) per 100, 000 population aged ≥15 years and
six percent of TB patients died in 2010[1]. Standard short-
course chemotherapy regimen, which comprises of a com-
bination of Isoniazid(H), Rifampicin(R), Pyrazinamide(Z),
Ethambutol(E) and Streptomycin(S) for 6–9 months is
recommended by WHO and currently used in most high
TB burden countries including China[2]. Due to the long
duration of therapy and concurrent use of multiple drugs,
adverse effects are regarded as the most important clinical
consideration in patients undergoing anti-TB treatment [3].
Hepatotoxicity is the most serious one, which not only
leads to high morbidity and mortality, but also diminishes
anti-TB treatment effectiveness owing to non-adherence
[4-7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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injury (ATLI) have been published and updated by the
American Thoracic Society (ATS), the British Thoracic
Society (BTS) and the Task Force of the European
Respiratory Society, the WHO and the International Union
Against Tuberculosis and Lung Disease [8-11]. Most of
these guidelines suggest the need of regular liver function
monitoring for preventing or alleviating ATLI, but all the
recommendations are based on expert opinion and/or clin-
ical experience of arbitrary authorities, which has not been
rigorously tested[8,12]. Besides, there is no consensus on
the frequency of monitoring. For example, the ATS recom-
mends monitoring every 2 to 4 weeks for patients with pos-
sible risk for hepatotoxicity, whereas BTS recommends
monitoring every week for the first 2 weeks and every fort-
night for another 2 months [9,10]. In contrast, China has
not published the relevant guideline of ATLI until now, and
there is no explicit suggestion on monitoring for TB
patients in China. No relevant study on the effect of regular
monitoring of liver function has been published.
To address the issue of the effect of regular monitoring
of transaminase during TB treatment, we conducted this
retrospective analysis based on a national-level cohort
study entitled ‘Anti-tuberculosis Drugs induced Adverse
Reactions in China National Tuberculosis Prevention and
Control Scheme Study (ADACS)’ [13,14]. Since the
ADACS study was not specially designed to evaluate the
effect of regular monitoring, only two routine tests (base-
line and within 2 months) were conducted, we described
“regular monitoring” as “scheduled monitoring” in this
study. The findings will provide evidence and suggestion
for developing management guidelines of ATLI in China.
Methods
Source population
Data were obtained from ADACS, which was approved by
the Ethics Committee of Center for Tuberculosis ControlPrimary treatment (n=3695) Ret
Recruited (n=4488) 












Figure 1 Flow chart of patients in ADACS.and Prevention of China and carried out from October
2007 to March 2009[13,14]. And written informed con-
sent was obtained from every participant or surrogate be-
fore enrolment. ADACS was a prospective longitudinal
study of anti-TB drugs induced adverse effects, which con-
sisted of a multi-center cohort of 4488 pulmonary TB
patients and receiving standard short-course chemother-
apy (primary and re-treatment patients would take HRZE/
HRZES for initial intensive phase and HR/HRE for con-
solidation phase respectively) in four geographically and
economically diverse areas of China[13,14]. During the
study, patients were asked to take liver function test at
baseline and within 2 months after treatment initiation in
addition to developing unbearable symptoms [13,14], and
for patients with abnormal baseline liver function the
anti-TB treatment would not be started until their liver
function turned normal through liver protective treat-
ment, so the baseline liver function was normal for all
patients. After the 6–9 months follow up period, 273
patients appeared liver dysfunction and 106 patients were
diagnosed as ATLI according to the ATS criteria [14]. Of
the 273 patients with liver dysfunction, 111 patients who
were diagnosed through scheduled liver function test
within two months after initiation of anti-TB treatment
formed scheduled monitoring group, others who were
diagnosed due to developing symptoms formed passive
detection group (n = 162) (Figure 1). In this study, we
compared the clinical features, prognosis of liver dys-
function and impact on anti-TB treatment between
the two groups to determine the effect of liver func-
tion monitoring on identification of asymptomatic
liver damage and anti-TB treatment outcomes during
anti-TB treatment. Besides, all patients were required
to fill in their ADACS calendars and record their
everyday feelings as well as drug usages during the
whole follow up period with the same pattern of
treatment supervision [13].Drop out (n=32)
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Liver dysfunction was diagnosed as an increase in serum
alanine aminotransaminase (ALT) or aspartate trans-
aminase (AST) or total bilirubin (TBil) that was greater
than the upper limit of normal (ULN), when other
causes were excluded: new viral hepatitis infections,
other liver diseases, other potentially hepatotoxic medi-
cations that would confound the picture. All assessments
were double checked by two experienced physicians.
The severity of liver dysfunction was classified according
to the WHO Toxicity Classification Standards [12]: mild
(ALT/AST ≤ 3 times ULN, or TBil ≤ 2 times ULN), mod-
erate (3 times ULN<ALT/AST ≤ 5 times ULN, or 2
times ULN< TBil≤ 5 times ULN) and severe (ALT/
AST/TBil> 5 times ULN).
During the follow-up in ADACS, when liver dysfunc-
tion developed, patients would be given intensive moni-
toring and/or treatment (such as liver protective drugs
or even hospitalization) according to the doctor’s clinical
adjudication. The anti-TB treatment would not be chan-
ged immediately, only when ALT/AST/TBil elevated to
greater than 2 times ULN, changes of anti-TB treatment
would be considered by the doctor, including drug re-
placement, interruption, discontinuation, dose decrease
and changes of medication administration.
Outcome measures
For comparison of the two groups, the following para-
meters were noted: 1) the time period for the develop-
ment of liver dysfunction from initiation of anti-TB
treatment (liver dysfunction finding time); 2) require-
ment of hospitalization; 3) severity of liver dysfunction;
4) prognosis of liver dysfunction, which was defined and
classified as recovered (ALT/AST/TBil turned normal),
continuing with abnormal ALT/AST/TBil and death; 5)
impact on anti-TB treatment.
Statistical analysis
The baseline characteristics and clinical features of parti-
cipants were described as median (inter-quartile range,
IQR) for continuous variables (not subject to normal
distribution), and percentages for categorical variables.
Non-parameter test was used for continuous variables
(not subject to normal distribution) and χ2 test was used
for categorical variables.
In order to control the confounding bias in this ob-
servational study, propensity score weighting was used
to compare the prognosis of liver dysfunction and im-
pact on anti-TB treatment between participants in
scheduled monitoring group and passive detection
group. A propensity score model was developed with
logistic regression model to predict patients’ assign-
ment in this cohort. Covariate variables included in
the model were as follows according to the selectionprinciple [15]: age, gender, weight, marriage status, in-
come per year, type of anti-TB treatment, history of
anti-TB adverse reactions, history of liver diseases,
HBSAg, pre-existing disease, pattern of taking anti-TB
drugs (every day or every other day), and type of pre-
ventive liver protective drugs [12,16]. Liver protective
drugs were classified as four categories (herbal pre-
parations, finished manufactured herbal products, combi-
nations of vitamins and other non-herbal substances, and
pharmaceutical preparations) according to a modified ver-
sion of WHO standard definitions for the evaluation and
research of herbal medicines [17,18]. After the calculation
of propensity score (PS), standardized mortality ratio
weighting (SMRW) was used to adjust the data with for-
mulas as follows:
Scheduled monitoring group: Wa ¼ 1;
Passive detection group:
Wb ¼ PS 1 Pað Þ½ = 1 PSð ÞPa½ ;
Pa is the percentage of scheduled monitoring
group in this cohort:
Then χ2 test was used to compare the prognosis of
liver dysfunction and impact on anti-TB treatment be-
tween the two groups.
The statistical analyses were performed using SPSS for
Windows (version 13.0; SPSS Inc.). A two-sided P value
less than 0.05 was set as the significant level.
Results
Baseline characteristics
Of the 273 patients with liver dysfunction, 111 patients
were in scheduled monitoring group while 162 patients
were in passive detection group. The baseline characteris-
tics of 273 patients were shown in Table 1. The median age
of 273 patients was 40.0 years (IQR: 28.0-53.0), and 212
(77.7%) were male. Among the demographic features and
weight, there was no significant difference between the
two study groups. And no statistically significant differ-
ence was found in type of anti-TB treatment, history of
anti-TB adverse reactions, history of liver diseases, HBSAg
and pattern of taking anti-TB drugs between the two
groups. 75 patients (67.6%) in scheduled monitoring group
and 94 (58.0%) in passive detection group took preventive
liver protective drugs during the anti-TB treatment
(P = 0.111). 57 (51.4%), 3 (2.7%), 5 (4.5%) and 10 (9.0%)
patients in scheduled monitoring group took finished
manufactured herbal preparations, combinations of vita-
mins and other non-herbal substances, pharmaceutical
preparations and combinations of above liver protective
drugs, respectively. On the contrary, 59 (36.4%), 5 (3.1%),
7 (4.3%) and 23 (14.2%) patients in passive detection group
Table 1 Baseline characteristics of 273 patients with liver dysfunction in ADACS





Age, median years (IQR) 40(29,53) 40(28,55) 0.243
Male 89(80.2%) 123(75.9%) 0.407
Married 86(77.5%) 130(80.1%) 0.697
Income per year, median¥(IQR) 10000(5000,20000) 10000(5000,15000) 0.647
Weight
<50 kg 27(24.3%) 44(27.2%) 0.600
≥50 kg 84(75.7%) 118(72.8%)
Type of anti-TB treatment
Primary treatment 95(85.6%) 143(88.3%) 0.514
Re-treatment 16(14.4%) 19(11.7%)
History of anti-TB adverse reactions
Yes 3(2.7%) 2(1.2%) 0.668
No 108(97.3%) 160(98.8%)
History of liver diseases*
Yes 7(6.3%) 9(5.6%) 0.795
No 104(93.7%) 153(94.4%)
HBSAg positive 21(18.9%) 32(19.8%) 0.940
Pattern of taking anti-TB drugs
Every day 9(8.1%) 17(10.5%) 0.510
Every other day 102(91.9%) 145(89.5%)
Usage of preventive liver protective drugs
Finished manufactured herbal preparations 57(51.4%) 59(36.4%) 0.145
Combinations of vitamins & other non-herbal substances 3(2.7%) 5(3.1%)
Pharmaceutical preparations 5(4.5%) 7(4.3%)
Combinations of above drugs 10(9.0%) 23(14.2%)
Note: *Including hepatitis B, icterohepatitis and cholelithiasis.
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above, respectively.
Clinical features
91 (33.3%) of 273 patients did not have any clinical symp-
toms, including 8 with severe hepatotoxicity. Among 111
patients in scheduled monitoring group, only 20 patients
(18.0%) developed symptoms of nausea (11 patients,
55%), vomiting (9 patients, 45%), anorexia (5 patients,
25%) and abdominal symptoms (4 patients, 20%) after
detecting liver dysfunction. None of the patients devel-
oped icterus and dark urine. All 162 patients (100%) in
passive detection group were symptomatic. 116 (71.6%),
110 (67.9%), 31 (19.2%) and 51 (31.5%) patients experi-
enced nausea, vomiting, anorexia and abdominal symp-
toms, respectively. 5 patients (3.1%) developed icterus
and 1 patient (0.6%) developed dark urine (Table 2).
The median interval in days between the initiation of
anti-TB treatment and the development of liver dysfunc-
tion was 52 (IQR: 30, 61) for scheduled monitoring groupand 39 (IQR: 28, 60) for passive detection group. The dif-
ference between patients in the two groups was not statis-
tically significant (P = 0.205) (Table 2).
In terms of the severity of liver dysfunction, more
patients (28 patients, 17.3%) in passive detection group
experienced severe liver dysfunction in comparison with
those in scheduled monitoring group (13 patients,
11.7%), although there was no statistically significant dif-
ference between the two groups (P = 0.443). Besides, 8
patients with severe hepatotoxicity in scheduled moni-
toring group did not have any clinical symptoms. Only 2
patients (1.8%) in scheduled monitoring group required
hospitalization, whereas in passive detection group a
total of 18 patients (11.1%) were hospitalized. The differ-
ence between the two groups was statistically significant
(P = 0.004) (Table 2). When analyzing patients with liver
dysfunction finding time less than 1 month, no one in
scheduled monitoring group required hospitalization in
contrast to 8 patients (11.9%) in passive detection group
(P = 0.025).
Table 2 Clinical features of liver dysfunction in the study groups
Clinical features Scheduled monitoring group (n= 111) Passive detection group (n = 162) P value
Symptomatic liver dysfunction 20 (18.0%) 162 (100.0%) <0.001
Liver dysfunction finding time, median, days (IQR) 52 (30, 61) 39 (28, 60) 0.205
Severity of liver dysfunction
Mild 70 (63.1%) 97 (59.9%) 0.443
Moderate 28 (25.2%) 37 (22.8%)
Severe 13 (11.7%) 28 (17.3%)
Requirement of hospitalization 2 (1.8%) 18 (11.1%) 0.004
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treatment
Regarding the prognosis of liver dysfunction, 1 patient in
passive detection group was excluded from the analysis
due to death of lung cancer. 109 patients (98.2%) recov-
ered, 2 patients (1.8%) continued with abnormal trans-
aminase, and none of the patients died in scheduled
monitoring group, whereas in passive detection group
158 patients (98.1%) recovered, 1 patient (0.6%) contin-
ued with abnormal transaminase, and 2 patients (1.3%)
died of hepatotoxicity. A 68 years old woman who
experienced ALT/AST elevation to 693.1/510.2 U/L after
35 days of anti-TB treatment was with no improvement
after hospitalization and finally died of hepatic failure on
the 45th day; another 69 years old man who experienced
ALT elevation to 210 U/L with jaundice after 65 days of
anti-TB treatment died after 1 week in hospital. The
propensity score weighting analysis showed that there
was not significantly different between the two groups
(P = 0.965).Table 3 Impact of liver dysfunction on anti-TB treatment








No change 72 (64.9%) 70 (43.2%)
Interruption 15 (13.5%) 48 (29.6%)
Dose decrease 4 (3.6%) 1 (0.6%)
Drug replacement 6 (5.4%) 11 (6.8%)
Discontinuation 2 (1.8%) 10 (6.2%)
Changes in medical
administration
3 (2.7%) 11 (6.8%)
Interruption with drug
replacement
7 (6.3%) 9 (5.6%)
Interruption with change
in medical administration
1 (0.9%) 1 (0.6%)
Dose decrease with change
in medical administration
1 (0.9%) 0 (0.0%)
Change in medical
with discontinuation
0 (0.0%) 1 (0.6%)




group (n = 111)
Passive detection
group (n = 158)*
P value
Cure on time 89 (80.2%) 112 (70.9%)
Prolongation 22 (19.8%) 43 (27.2%) 0.084
Aggravation 0 (0.0%) 1 (0.6%)
Death 0 (0.0%) 2 (1.3%)
Note: * 4 patients were excluded due to lost to follow up after discontinuation
and death of lung cancer.
# P value was calculated after propensity score weighting analysis.In scheduled monitoring group, 39 patients (35.1%)
changed their anti-TB treatment, whereas 92 patients
(56.8%) in passive detection group changed the treat-
ment. The difference was statistically significant by pro-
pensity score weighting analysis (P = 0.001). As shown in
Table 3, more patients in passive detection group inter-
rupted and discontinued the anti-TB treatment in com-
parison with patients in scheduled monitoring group
(P = 0.007 and P= 0.026, respectively).
When analyzing the impact of liver dysfunction on TB
condition, 4 patients in passive detection group were
excluded because they could not be followed up for TB
treatment outcomes due to discontinuation after the
onset of hepatotoxicity (3 patients) and death of lung
cancer (1 patient). 89 patients (80.2%) in scheduled
monitoring group and 112 patients (70.9%) in passive
detection group had TB cured on time. None of the
patients had TB aggravated or died in scheduled moni-
toring group, whereas there was 1 (0.6%) with TB aggra-
vation and 2 (1.3%) deaths in passive detection group
(Table 4).Discussion
This study was based on a well-established prospective
cohort and reflected the effect of routine monitoring in
a real-world population with geographically and eco-
nomically diverse areas in China. However, a major
methodological problem in this observational study is
that investigators have no control over the intervention
assignment, which is likely to result in confounding and#
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count for these differences in observed covariates, pro-
pensity scores were applied in this analysis.
Among several propensity score methods, SMRW and
matching estimated most closely approached results
observed in the clinical trials [23]. In comparison with
matching, SMRW has more advantages [24]: 1) data
from all patients are used so that variance is more
closely to the study population; 2) process for SMRW is
much easier than propensity score matching. Based on
all above, we used SMRW to balance all available covari-
ates and estimate the effect of routine monitoring in this
study.
In the present study, 1/3 of the patients with liver dys-
function did not have any clinical symptoms, including 8
with severe hepatotoxicity, which indicated the import-
ant role of routine monitoring in identifying asymptom-
atic liver injury. Liver injury could be fatal if it was not
recognized in time [12], thus routine monitoring could
be helpful to detect liver damage early so as to apply ap-
propriate interventions in time and improve the progno-
sis. Our results showed that there was no death and only
2 patients (1.8%) in hospital in scheduled monitoring
group. 35.1% changed their anti-TB treatment. In con-
trast, in passive detection group 11.1% required
hospitalization and 2 patients (1.3%) died. More than
half of the patients changed their anti-TB treatment.
Therefore, routine liver function monitoring was asso-
ciated with less hospitalization, better prognosis and bet-
ter compliance of anti-TB treatment in this study. A
study by Agal et al. [25] showed that 21 (10.5%) of
200 TB patients who accepted regular liver function
monitoring (every week for the first month, then fort-
nightly for the next 2 months and then monthly until
the end of therapy) developed ATLI and no one died,
whereas 16.6% of the patients without periodic monitor-
ing died and 75% developed icteric hepatitis. In a study
by Mcneill et al. [26], the rate of severe ATLI in patients
receiving RZ prophylaxis for latent tuberculosis infection
(LTBI) reduced from 5% to 0% with periodic monitoring.
Another study [27] with H prophylaxis for LTBI indi-
cated that no severe ATLI developed on routine
monitoring.
Biochemical abnormalities generally occur before clin-
ical symptoms or signs of liver injury develop, thus mon-
itoring of liver function can detect liver injury ahead of
the symptomatic period, prevent serious ATLI and avoid
incompliance of anti-TB treatment [12,16]. In our study,
the median liver dysfunction finding time of passive detec-
tion group was 39.0 days, which indicated that monitoring
in the first month after the initiation of anti-TB treatment
was important. Subgroup analysis for patients with liver
dysfunction finding time less than 1 month showed that
significantly more patients required hospitalization inpassive detection group. More patients in passive detec-
tion group changed their anti-TB treatment and were
likely to have a poor prognosis of hepatotoxicity, although
there was no significant statistically difference between
the two groups.
Some limitations need to be noted. First, the ADACS
study was not specially designed to evaluate the effect of
regular liver function monitoring, only two routine tests
(baseline and within 2 months after initiation of anti-TB
treatment respectively) were conducted, thus it may
limit the ability of detecting liver dysfunction earlier.
Secondly, although we controlled a large set of factors
that potentially differed between the groups at baseline
using propensity score method, there are still some un-
known confounders which may not be balanced. Propen-
sity scores are not magic bullets capable of eliminating
all the bias of observational studies [28]. Besides, the
study did not collect patients’ information on HIV infec-
tion and alcohol consumption which are important risk
factors of hepatotoxicity. Finally, owing to the only two
routine tests in our study, it is still not clear what fre-
quency or intervals between tests may be optimal. And
further studies on compliance and cost effectiveness of
monitoring are needed.
Conclusions
In conclusion, scheduled monitoring is effective in identi-
fying asymptomatic liver damage, reducing hospitalization
rate and improving compliance of anti-TB treatment. It
is likely to alleviate hepatotoxicity and reduce mortality.
At least once monitoring should be performed during
the first month after initiation of anti-TB treatment, and
monitoring in the second month is highly suggested if
available.
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